Evidence map›Paper›PMID 24956489›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2014

Agile delivery of protein therapeutics to CNS.

Xiang Yi, Devika S Manickam, Anna Brynskikh, Alexander V Kabanov

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Brain Targeting Nanomedicines: Pitfalls and Promise.International journal of nanomedicine · 2024
    Review
  12. Article
  13. Review
  14. Article
  15. Transporter-Mediated Drug Delivery.Molecules (Basel, Switzerland) · 2023
    Review
  16. Transferrin Aptamers Increase theBioconjugate chemistry · 2022
    Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Xiang YiDivision of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: xiang_yi@unc.edu.
Devika S ManickamDivision of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Anna BrynskikhDepartment of Pharmaceutical Sciences and Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Alexander V KabanovDivision of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Faculty of Chemistry, M.V. Lomonosov Moscow State University, 119899 Moscow, Russia. Electronic address: akabanov@email.unc.edu.
University of North Carolina at Chapel Hill · USUniversity of Nebraska Medical Center · US

Funding

Project 9 - Renal Drug Targeting for the Treatment of Lupus NephritisP20GM103480 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BRONICH, TATIANA K · 2012 to 2017
$13.3M
TARGETED NANOCARRIER FOR SIRNA DELIVERY TO TUMOR VASCULATUREP20RR021937 · NCRR · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI POLUEKTOVA, LARISA Y · 2008 to 2011
$8.6M
Polypeptide Modification for Enhanced Brain DeliveryR01NS051334 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BANKS, WILLIAM A, KABANOV, ALEXANDER V · 2006 to 2014
$2.7M
INTERACTIONS OF BLOCK COPOLYMERS IN BLOOD BRAIN BARRIERSR01NS036229 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI KABANOV, ALEXANDER V · 1997 to 2006
$1.9M
NCRR NIH HHS P20 RR021937NIGMS NIH HHS P20 GM103480NINDS NIH HHS R01 NS036229NINDS NIH HHS R01 NS051334
6 · The paper itself

Abstract

A variety of therapeutic proteins have shown potential to treat central nervous system (CNS) disorders. Challenge to deliver these protein molecules to the brain is well known. Proteins administered through parenteral routes are often excluded from the brain because of their poor bioavailability and the existence of the blood-brain barrier (BBB). Barriers also exist to proteins administered through non-parenteral routes that bypass the BBB. Several strategies have shown promise in delivering proteins to the brain. This review, first, describes the physiology and pathology of the BBB that underscore the rationale and needs of each strategy to be applied. Second, major classes of protein therapeutics along with some key factors that affect their delivery outcomes are presented. Third, different routes of protein administration (parenteral, central intracerebroventricular and intraparenchymal, intranasal and intrathecal) are discussed along with key barriers to CNS delivery associated with each route. Finally, current delivery strategies involving chemical modification of proteins and use of particle-based carriers are overviewed using examples from literature and our own work. Whereas most of these studies are in the early stage, some provide proof of mechanism of increased protein delivery to the brain in relevant models of CNS diseases, while in few cases proof of concept had been attained in clinical studies. This review will be useful to broad audience of students, academicians and industry professionals who consider critical issues of protein delivery to the brain and aim developing and studying effective brain delivery systems for protein therapeutics.

Indexed as

Drug CarriersBlood-Brain BarrierCentral Nervous System DiseasesHumansNanoparticlesPeptidesProteinsDrug CarriersPeptidesProteinsAdministration routeBlood–brain barrierBrain deliveryCentral nervous systemProtein deliveryProtein therapeutics

Identifiers

PMID24956489
PMCPMC4142106
OpenAlexW2076616450

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.